Correction: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type (PLoS Pathogens (2020) 15:12 (E1008121) DOI: 10.1371/journal.ppat.1008121)

Luca Schifanella, Susan W Barnett, Massimiliano Bissa, Veronica Galli, Melvin N Doster, Monica Vaccari, Georgia D Tomaras, Xiaoying Shen, Sanjay Phogat, Ranajit Pal, David C Montefiori, Celia C LaBranche, Mangala Rao, Hung V Trinh, Robyn Washington-Parks, Namal P M Liyanage, Giacomo Gorini, Dallas R Brown, Frank Liang, Karin LoréDavid J Venzon, William Magnanelli, Michelle Metrinko, Josh Kramer, Matthew Breed, Galit Alter, Ruth M Ruprecht, Genoveffa Franchini

Research output: Contribution to journalComment/debatepeer-review

Abstract

[This corrects the article DOI: 10.1371/journal.ppat.1008121.].

Original languageEnglish (US)
Article numbere1008531
Pages (from-to)e1008531
JournalPLoS pathogens
Volume16
Issue number4
DOIs
StatePublished - Apr 2020

Bibliographical note

Publisher Copyright:
© 2020 Public Library of Science. All rights reserved.

PubMed: MeSH publication types

  • Published Erratum
  • Journal Article

Fingerprint

Dive into the research topics of 'Correction: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type (PLoS Pathogens (2020) 15:12 (E1008121) DOI: 10.1371/journal.ppat.1008121)'. Together they form a unique fingerprint.

Cite this